What Is Paclitaxel (Taxol)? FDA Approval, Licensing in Turkey, and Reimbursement Status

• FDA Approval: Yes (Initial approval: December 29, 1992)
• Brand Name: Taxol
• Active Ingredient: Paclitaxel
• Route of Administration: Intravenous (IV injection)
• Class: Microtubule Inhibitor (Antimitotic Agent)
• Category: Nontargeted Chemotherapeutic Agent
• Manufacturer: Bristol-Myers Squibb
• Availability in Turkey: Bristol-Myers Squibb Turkey and equivalent generic manufacturers
• Approved Cancers: Ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), AIDS-related Kaposi sarcoma, pancreatic cancer (with the nab-paclitaxel formulation), cervical cancer, and head and neck cancer

What Is Paclitaxel (Taxol)? How Does It Work? 

Paclitaxel is a taxane chemotherapy drug obtained from Taxus brevifolia (the Pacific yew tree). Scientists were screening plant extracts for potential anticancer agents when they discovered paclitaxel's pronounced cytotoxic properties against cancer cells. The compound's ability to prevent microtubule depolymerization, leading to cell cycle arrest and apoptosis, intrigued researchers and paved the way for extensive investigation. 

How Does It Work? 

• Paclitaxel is a chemotherapy drug belonging to the antimicrotubule class. It acts on microtubules, important components of the cell's cytoskeleton. These structures ensure proper chromosome separation during cell division, consist of protein subunits called tubulin, and have a dynamic structure.
• Paclitaxel disrupts this dynamic process by binding to β-tubulin subunits, the building blocks of microtubules. Microtubules normally form and break down continuously; paclitaxel halts this cycle, turning them into stable structures that do not disassemble. This prevents microtubules from carrying out their normal functions.
• During cell division, structures called mitotic spindles ensure that chromosomes separate correctly. Paclitaxel disrupts spindle formation, preventing proper chromosome separation. This causes cell cycle arrest at the G2/M phase. The cell cannot continue dividing at this stage, and mitosis cannot occur.
• When this cell cycle arrest persists, cells initiate programmed cell death, called apoptosis. This mechanism occurs when a cell recognizes itself as damaged or dysfunctional. In this way, paclitaxel stops cancer cells from proliferating and destroys them.
• Rapidly dividing cancer cells are particularly sensitive to paclitaxel because they depend more heavily on microtubule dynamics. Through this property, paclitaxel selectively targets cancer cells and stops tumor growth by inhibiting their ability to divide.

FDA (United States Food and Drug Administration) Approval History

• December 29, 1992: It received its first FDA approval for the treatment of advanced ovarian cancer. This established paclitaxel as a groundbreaking agent in chemotherapy.
• June 17, 1994: It was approved for metastatic breast cancer. This indication is particularly important for patients who do not respond to anthracycline-based treatments.
• September 30, 1998: It was approved in combination with cisplatin for the treatment of non-small cell lung cancer (NSCLC).
• February 11, 1999: It received FDA approval for the treatment of AIDS-related Kaposi sarcoma.
• 2005 onward: The albumin-bound formulation of paclitaxel (nab-paclitaxel / Abraxane) was approved for various indications.

Licensing in Turkey 

The situations in which paclitaxel is licensed in Turkey / its therapeutic indications are specified as follows:

Therapeutic Indications:

• Ovarian Cancer: Indicated in combination with a platinum-containing drug as first-line treatment for advanced or metastatic ovarian cancer, and as second-line treatment for advanced or metastatic ovarian cancer.
• Breast Cancer: Early-stage adjuvant treatment: Indicated as adjuvant treatment for node-positive breast cancer following anthracycline and cyclophosphamide therapy.
• First-line treatment of advanced or metastatic breast cancer: Indicated in combination with an anthracycline when anthracycline treatment is appropriate; as a single agent when anthracycline treatment is inappropriate; or in combination with trastuzumab in patients whose HER-2 status is strongly positive by immunohistochemistry (3 positive or positive by FISH).
• Indicated as second-line treatment for metastatic breast cancer after failure of combination chemotherapy. First-line treatment should have included an anthracycline unless clinically contraindicated.
• Indicated in combination with a platinum compound as first-line treatment for non-small cell lung cancer in patients who will not undergo potentially curative surgery or radiotherapy.
• Indicated as second-line treatment for AIDS-related Kaposi sarcoma.

Is Paclitaxel Reimbursed?

Paclitaxel is reimbursed by the Social Security Institution (SGK) in Turkey. It is on the list of drugs for which no indication restriction applies in patients diagnosed with cancer and is reimbursed by SGK for all cancer diagnoses.

Price: A paclitaxel 100 mg vial costs 398.72 TL, and a paclitaxel 30 mg vial costs 134.02 TL.

Mechanisms of Resistance 

• Although paclitaxel is an effective chemotherapy drug against many types of cancer, cellular resistance mechanisms developing over time can reduce treatment effectiveness. Resistance may be present before treatment begins (primary resistance) or acquired during treatment (secondary resistance).
• One of the most important contributors to paclitaxel resistance is increased expression of P-glycoprotein (P-gp), a transporter protein in the cell membrane that expels foreign substances. This protein reduces the drug's effectiveness by preventing it from reaching sufficient levels inside the cell. This is particularly common in multidrug-resistant (MDR) cancer cells.
• Structural changes may also occur in tubulin, the protein to which paclitaxel binds directly. These changes weaken the drug's ability to bind to microtubules and prevent microtubule stabilization. This eliminates paclitaxel's effect of halting cell division.
• Disruption of intracellular signaling pathways may also contribute to resistance. In particular, weakened apoptosis (programmed cell death) mechanisms prevent a cell from dying even when damaged. In this situation, the cell continues to survive even if paclitaxel arrests the cell cycle.
• Changes in the expression or activity of microtubule-associated proteins (such as MAPs) may also promote resistance. These proteins regulate microtubule structure and can help cells adapt to paclitaxel's effects.
• In summary, paclitaxel resistance is a multifactorial process. Many stages can influence resistance, from drug entry into the cell and target binding to the cell's response to death signals. Different drug combinations or targeted treatment strategies may therefore be considered in patients who develop resistance.

Absorption

It is administered intravenously. Following intravenous administration, paclitaxel plasma concentrations show a biphasic
decline. At doses of 135 and I75 mg/m2 and infusion durations of 3 and 24 hours, the mean terminal half-life
ranges from 13.1- 52.7 hours, and total body clearance is between 12.2 and 23.81 / hour/ m2.

Distribution 

When administered intravenously, paclitaxel rapidly distributes into tissues. It can reach particularly high concentrations in the liver, lungs, spleen, and tumor tissues. It is highly bound (89–98%) to plasma proteins, particularly carrier proteins such as albumin and alpha-1-acid glycoprotein. Its large volume of distribution indicates extensive distribution into extravascular tissues.

Metabolism 

Approximately 90% of paclitaxel is metabolized in the liver by the cytochrome (CYP) P450 enzyme system, particularly the CYP2C8 and CYP3A4 isoenzymes. The main metabolic pathway involves hydroxylation of the side chain at the C13 position, forming several metabolites, including 6α-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel. These metabolites are pharmacologically less active than the parent drug.

Dose Range 

Breast Cancer: Paclitaxel is generally administered in weekly regimens or every 3 weeks.

• Weekly dose: 80–100 mg/m² (usually infused over 1 hour)
• Dose every 3 weeks: 175 mg/m² (intravenous infusion over 3 hours)

Ovarian Cancer: Usually used in combination with carboplatin as first-line treatment.

• Dose: 135–175 mg/m² (usually infused over 3 hours, every 21 days)

Non-Small Cell Lung Cancer (NSCLC): Paclitaxel is generally administered with carboplatin.

• Dose: 175 mg/m² (infused over 3 hours, every 3 weeks)

AIDS-Related Kaposi Sarcoma: Lower doses are administered in this patient group.

• Dose: 100 mg/m² (every 3 weeks or according to clinical status)

Pancreatic Cancer (nab-paclitaxel formulation):

• Dose: 125 mg/m², administered on 3 days per week (days 1, 8, and 15)

Head and Neck and Cervical Cancers: Usually used in combination with radiotherapy or added to platinum-based chemotherapy regimens.

• Doses may vary according to clinical trials but are most commonly in the range of 135–175 mg/m².

Drug Interactions 

• Paclitaxel is a chemotherapy agent that can interact with many drugs. These interactions can affect how the drug is processed in the body (metabolism, distribution, and elimination), potentially reducing effectiveness and increasing the risk of adverse effects.
• Paclitaxel is metabolized by hepatic cytochrome P450 (CYP) enzymes. CYP2C8 and CYP3A4 play particular roles in this process. Other drugs that affect these enzymes can directly influence how long paclitaxel remains in the blood and at what concentration.
• CYP2C8 and CYP3A4 Inhibitors: Drugs and substances such as ketoconazole, erythromycin, clarithromycin, fluoxetine, and grapefruit juice inhibit these enzymes. This slows paclitaxel elimination, increases plasma concentrations, and may increase toxic effects.
• CYP2C8 and CYP3A4 Inducers: Substances such as rifampin, phenytoin, carbamazepine, and St. John's wort can stimulate these enzymes and cause paclitaxel to be metabolized more rapidly. This can lower its plasma concentration and reduce its effect.
• P-gp Inhibitors: Paclitaxel is also a substrate of a transporter protein called P-glycoprotein (P-gp). P-gp pumps the drug out of cells and is particularly active in the intestine, blood-brain barrier, and tumor tissues. Drugs that affect this transporter can alter paclitaxel distribution and effectiveness in the body. Drugs such as verapamil, quinidine, and amiodarone can inhibit P-gp, causing paclitaxel to accumulate inside cells and increasing systemic exposure. This may increase the risk of adverse effects.
• P-gp Inducers: Drugs such as rifampin and carbamazepine stimulate P-gp, causing paclitaxel to be pumped out of cells more rapidly. This may prevent the drug from reaching sufficient levels in the blood and target tissues.

Precautions

• Allergic Reactions: Paclitaxel can cause serious hypersensitivity reactions, particularly because of substances used as carrier solvents. Premedication generally includes an antihistamine, a corticosteroid, and an H2 receptor blocker. If signs such as flushing, shortness of breath, or low blood pressure develop during treatment, the infusion should be stopped immediately.
• Bone Marrow Suppression: Paclitaxel suppresses bone marrow, most commonly causing neutropenia (a reduced white blood cell count). This increases infection risk. Complete blood counts should therefore be monitored regularly during treatment. Severe neutropenia may require dose reduction or a treatment interruption.
• Liver Dysfunction: Because paclitaxel is metabolized in the liver, it may accumulate in patients with impaired liver function, increasing toxicity risk. Dose adjustments should be made in these patients, and liver enzymes should be monitored closely.
• Neurotoxicity: Damage to the peripheral nervous system may cause peripheral neuropathy, particularly during prolonged treatment. If symptoms such as numbness or tingling in the hands and feet occur, the treatment dose should be reduced or treatment temporarily stopped.
• Cardiac Effects: Cardiac rhythm disturbances such as bradycardia, arrhythmias, and conduction abnormalities have been reported, albeit rarely. Caution is required in patients with a history of heart disease, and ECG monitoring may be needed.
• Pregnancy and Breastfeeding: Paclitaxel may harm embryonic/fetal development. It should not be used during pregnancy. Its use is also not recommended during breastfeeding because it may pass into breast milk. Women of reproductive potential should use effective contraception during treatment.
• Interactions With Other Drugs: Paclitaxel can interact with many drugs. Particular caution is needed with drugs that affect liver enzymes (CYP2C8 and CYP3A4 inhibitors/inducers) and agents that affect P-glycoprotein transporters.
• Venous Irritation and Extravasation: Leakage of the drug outside the vein during infusion can cause local tissue damage. The infusion should therefore be administered carefully, with a secure intravenous line.

Adverse Effects 

The most frequently reported adverse effects of paclitaxel in clinical trials:

• Neutropenia (low white blood cell count): 60–90%
• Alopecia (hair loss): 80–100%
• Peripheral neuropathy: 60–70%
• Anemia (low red blood cell count): 40–50%
• Thrombocytopenia: 5–25%
• Nausea and vomiting: 40–60%
• Diarrhea: 30–50%
• Mouth sores (stomatitis): 15–30%
• Loss of appetite (anorexia): 20–30%
• Fever: 10–25%
• Hypersensitivity reactions (rash, itching, flushing): 10–15%
• Skin rash: 5–10%
• Bradycardia (slow heart rate): 1–5%
• Arrhythmia (abnormal heart rhythm): 1–5%
• Elevated liver enzymes: 5–15%
• Musculoskeletal pain (myalgia/arthralgia): 30–60%
• Anaphylactic reactions: 1%
• Convulsions (seizures): 0.1%
• Severe allergic reactions (angioedema, shortness of breath): 0.1%